12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CNV2197944: Phase I started

Convergence began a placebo-controlled, U.K. Phase I trial to evaluate single ascending-doses of oral CNV2197944 in...

Read the full 56 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >